Nov 5, 2026 · 31 min
Retatrutide’s weight-loss gains raise a muscle-preservation question
Does Retatrutide Cause Muscle Loss? The TRIUMPH-1 Phase 3 Results Explained
Retatrutide’s unprecedented results could reshape obesity treatment, but incomplete body-composition data leaves its effect on muscle unresolved.
- 1Retatrutide produced roughly 25% average weight loss over 80 weeks, with some participants losing 30% or more.
- 2The trial reported broad metabolic and functional improvements, including changes in blood pressure, triglycerides, prediabetes, knee osteoarthritis, and sleep apnea.
- 3Protein intake and resistance training emerge as essential safeguards because rapid weight loss can include substantial lean-tissue loss.
Don't miss
Lyon turns the impressive weight-loss headline into a sharper clinical question by emphasizing that the trial did not adequately establish how much muscle was lost.
The brief
Dr. Gabrielle Lyon examines TRIUMPH-1, where investigational retatrutide produced roughly 25% average weight loss over 80 weeks and pushed some participants beyond 30%.
The episode places the scale of loss alongside improvements in waist circumference, blood pressure, triglycerides, insulin, inflammation, prediabetes, knee osteoarthritis, and sleep apnea.
Its central tension is measurement: the trial did not adequately report body composition, so the headline result cannot show how much muscle participants lost.
Lyon argues that adequate protein and resistance training are the practical tools for preserving skeletal muscle and improving the quality of rapid weight loss.
Retatrutide remains investigational, and its triple-agonist mechanism, side effects, dosing, and lack of direct comparison with tirzepatide keep the results from settling the broader debate.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.